|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:auditedBy
|
gptkb:PricewaterhouseCoopers_LLP
|
|
gptkbp:CEO
|
gptkb:Christopher_A._Viehbacher
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
09062X103
|
|
gptkbp:dividendPaying
|
does not pay regular dividends
|
|
gptkbp:filingsInclude
|
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0000875045
|
|
gptkbp:focusArea
|
gptkb:Alzheimer's_disease
multiple sclerosis
rare diseases
neurological diseases
spinal muscular atrophy
|
|
gptkbp:foundedYear
|
1978
|
|
gptkbp:founder
|
gptkb:Phillip_Sharp
gptkb:Walter_Gilbert
|
|
gptkbp:hasCompany
|
gptkb:Biogen_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NASDAQ: BIIB
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US09062X1037
|
|
gptkbp:marketCap
|
varies (check latest financial data)
|
|
gptkbp:numberOfEmployees
|
approximately 8,700 (2023)
|
|
gptkbp:previousName
|
gptkb:Biogen_Idec
|
|
gptkbp:products
|
gptkb:Aduhelm
gptkb:Avonex
gptkb:Fampyra
gptkb:Plegridy
gptkb:Spinraza
gptkb:Tecfidera
gptkb:Tysabri
gptkb:Leqembi
|
|
gptkbp:SIC
|
2836
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Biogen_Idec_Ltd.
|
|
gptkbp:tickerType
|
gptkb:stock_market_index
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:website
|
https://www.biogen.com/
|
|
gptkbp:bfsParent
|
gptkb:Biogen_Idec
|
|
gptkbp:bfsLayer
|
6
|